Founded in 1947, Dana-Farber Cancer Institute is a Harvard Medical School teaching hospital that U.S. News & World Report consistently ranks the No. 1 cancer hospital in New England and among the best in the nation. It is the only hospital ranked in the top three nationally for both adult and pediatric cancer care. Dana-Farber partners with Boston-based Brigham and Women’s Hospital and Boston Children’s Hospital to deliver integrated care, with the Dana-Farber Brigham Cancer Center providing comprehensive adult cancer care across Dana-Farber’s Longwood (Mass.) campus and an inpatient hospital located within Brigham and Women’s Hospital. Meanwhile, the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center has been ranked the No. 1 pediatric cancer hospital by U.S. News & World Report more often than any other program. Dana-Farber Cancer Institute records 600,000 outpatient visits annually while supporting more than 1,200 clinical trials, and its faculty publishes more than 1,200 scientific articles each year, driving advances that shape cancer research and care around the world. A recent study published by the National Bureau of Economic Research shows that Dana-Farber Cancer Institute has the highest scientific output per researcher of any institution in the world. In early 2026, Dana-Farber began the construction process for a new 300-bed adult inpatient hospital, which will grow capacity and increase access to specialized cancer care. Dana-Farber is a founding member of the Harvard Cancer Consortium, and is one of the largest recipients of National Cancer Institute grant funding, supporting 90 National Institutes of Health-sponsored research grants, 173 principal investigators and 764 research fellows. The institute trains 84 clinical fellows across adult and pediatric oncology.
